Stepan posted a first-quarter 2026 net loss of $41.4 million, reversing a $19.7 million profit a year earlier, as a $65.4 million pre-tax restructuring charge tied to site closures and asset decommissioning hit results.
Revenue rose 2% to $604.5 million from $593.3 million, helped by higher selling prices and foreign currency translation, which more than offset a 3% decline in sales volume. Organic sales volume was flat.
Adjusted net income fell 47% to $10.3 million from $19.3 million, while adjusted earnings per diluted share dropped 46% to 45 cents from 84 cents.
EBITDA swung to a negative $16.5 million from $58.0 million a year earlier. Adjusted EBITDA declined 14% to $49.6 million from $57.5 million.
By segment, surfactant sales increased 5% to $453.7 million, polymers sales fell 11% to $130.0 million, and specialty products sales rose 24% to $20.8 million.
Segment operating income totaled $32.1 million, down 24% from $42.5 million. Surfactants operating income fell 36% to $18.5 million, polymers rose 10% to $8.8 million, and specialty products declined 14% to $4.7 million.
Adjusted EBITDA for surfactants dropped 15% to $41.1 million, polymers increased 8% to $17.4 million, and specialty products fell 11% to $6.2 million. Unallocated corporate adjusted EBITDA was a negative $15.1 million, versus a negative $13.9 million last year.
Cash from operations was $16.9 million, while free cash flow was negative $14.0 million after $30.9 million of capital expenditures. Today the company's shares have moved 0.56% to a price of $52.06. If you want to know more, read the company's complete 8-K report here.
